Back to top
more

TELESIS BIO (TBIO)

(Delayed Data from NSDQ)

$0.32 USD

0.32
26,223

0.00 (-0.93%)

Updated Apr 26, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cronos (CRON) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q2 results.

Sanofi (SNY) Q2 Earnings Top Estimates, Sales Lag, EPS View Up

by Zacks Equity Research

Sanofi (SNY) beats Q2 estimates for earnings while missing the same for sales. Gain from COVID-19 associated patient stockpiling in the first quarter reverses in this quarter. Stock up.

Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.

Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.

Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.

What to Expect for Applied Therapeutics (APLT) Q2 Earnings

by Zacks Equity Research

During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.

Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?

by Zacks Equity Research

On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.

Translate Bio, Inc. (TBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Translate Bio, Inc. (TBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Translate Bio (TBIO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (TBIO) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes

by Zacks Equity Research

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study

by Zacks Equity Research

Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.

Heron Therapeutics (HRTX) in Focus: Stock Moves 9% Higher

by Zacks Equity Research

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Spectrum Pharma (SPPI) Soars: Stock Adds 9.2% in Session

by Zacks Equity Research

Spectrum Pharma (SPPI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zomedica (ZOM) in Focus: Stock Moves 7.2% Higher

by Zacks Equity Research

Zomedica (ZOM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1%

by Zacks Equity Research

Citius Pharmaceuticals (CTXR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Are Options Traders Betting on a Big Move in Translate Bio (TBIO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Translate Bio (TBIO) stock based on the movements in the options market lately.

Translate Bio (TBIO) in Focus: Stock Moves 11.7% Higher

by Zacks Equity Research

Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Translate Bio Up on Vaccine Agreement Expansion With Sanofi

by Zacks Equity Research

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.

Company News for Jun 24, 2020

by Zacks Equity Research

Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.

Sanofi Expands Agreement With Translate Bio for mRNA Vaccines

by Zacks Equity Research

Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. The companies are already developing a mRNA vaccine candidate to combat COVID-19.

Sanofi (SNY) to Create Dedicated Vaccine Center in France

by Zacks Equity Research

Sanofi (SNY) plans to invest almost $690 billion to develop a new production site and research center in France with both dedicated to vaccines.

Will Translate Bio Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor of Translate Bio

Moderna Rallies on Encouraging Coronavirus Vaccine Study Data

by Zacks Equity Research

Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.

Translate Bio Inc (TBIO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Translate Bio Inc (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.